NasdaqGS:ALNYBiotechs
How Investors May Respond To Alnylam (ALNY) Expanding Cardiovascular RNAi Targets Through Tenaya Collaboration
Tenaya Therapeutics recently announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular disease over two years, with Tenaya receiving up to US$10,000,000 upfront plus cost reimbursement and potential milestone payments of up to US$1.13 billion if all targets lead to approved therapies.
This agreement could broaden Alnylam’s RNAi pipeline beyond its core transthyretin focus by adding genetically validated cardiovascular targets that...